The technical team formed for the evaluation of the proposals presented by the companies in the bidding for 129 medicines, whose shortages are critical in the Social Security Fund, must announce this week the names of the suppliers that are awarded the purchase.
Once the technical team announces the companies that were winners in the two tenders that are carried out for the purchase of these drugs, they will have 15 days to deliver them to the CSS, counted from the award of the contracts.
Around 49 companies presented proposals on April 12, in the two tenders carried out by the CSS for the purchase of these drugs.
The purchase process was carried out through the “online quotation” modality and the interested companies –national and international– presented their drug price proposals in this format.
In the act, some 32 companies presented proposals in 61 of the 129 lines. In this tender, the CSS seeks to buy drugs such as lopinavir, dicloxacillin, pyridoxine, loprazolam, simvastatin, amlodipine, among others.
In the other public act, convened for the purchase of 68 drugs, including complex B, lisinopril, dexamethaxone, among others, 17 companies were interested.
Through Executive Decree 36 of March 24, 2022, the Ministry of Health (Minsa) declared a critical shortage of 130 CSS medicines.
However, the director of the CSS, Enrique Lau Cortés, reported that ranitidine was excluded from the list due to an alert from the National Directorate of Pharmacy and Drugs, and for that reason only 129 medicines were tendered.
